	Appendix to Issue	Page
Table showing comparative prices of drugs in different countries and in Canada	C	26	1742
Submission of the Government of the Province of Alberta	D	26	1743-60
Supplementary Submission of PMAC			
Letter to the Chairman of the Committee from the President of the Canadian Wholesale Drug Association, Nov. 15, 1966	A	27	1810-37
Brief of the Canadian Wholesale Drug Association	B	27	1838-44
Brief of the Canadian Pharmaceutical Association, Inc.	A	28	1873-84
Supplementary Brief of Canadian Pharmaceutical Association, Inc.	A	29	1931-50
Submission from The Canadian Drug Manufacturers on the subject matter of Sales Tax on Pharmaceuticals	A	30	2089-99
Summary of Data on Drugs, FDD	B	30	2100-07
Some Observations on Drug Control in Europe	C	30	2108-13
Examination of Trifluoperazine Tablets Marketed in Canada	D	30	2114-35
Correspondence relating to the question of the "new drug" status of Trifluoperazine, and to the recommendations of the Hillard Committee in this regard	E	30	2136-46
Letter to the Legal Counsel for the Committee from the Executive Vice-President of PMAC	F	30	2147-48
Letter from the Solicitor for Hoffmann-La Roche re: Submission of Micro Chemicals Limited, Gryphon Laboratories Limited and Paul Maney Laboratories Canada Limited	G	30	2149-51
Letter from the Assistant Secretary of Hoffmann-La Roche Limited to the Chairman of the Committee	H	30	2152-53
Report entitled "The Cost of Pharmaceuticals and Medicines in Canada, 1961-1965"	A	32	2257-82
Letter from the Hon. Minister of National Health and Welfare to the Chairman of the Committee (Jan. 27, 1967)	B	32	2283
Letter from the Accountant of the Committee enclosing extracts of statistics for the Pharmaceutical Manufacturing Industry in Canada	A	33	2401-04
Letter from the Chairman of Canadian Drug Manufacturers, and a proposed description on the sales tax on pharmaceuticals	B	33	2405-06
Letter from the Registrar of the Pharmaceutical Association of the Province of British Columbia, with reference to brief presented by Mr. S. S. Bass, of London Drugs	C	33	2407-10
Letter from the Vice-President and Managing Director of Parke, Davis & Company, Ltd. supplying additional information	D	33	2411